血小板自身抗体特异性与原发性免疫性血小板减少症患者对 rhTPO 治疗的反应。
Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia.
机构信息
Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Shandong Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
出版信息
Br J Haematol. 2021 Jul;194(1):191-194. doi: 10.1111/bjh.17510. Epub 2021 May 15.
This retrospective study aimed to evaluate the relationship between plasma autoantibody species and rhTPO response in adult ITP patients who failed the first-line treatments. Plasma anti-glycoprotein (GP) IIb/IIIa and anti-GPIb/IX autoantibodies were detected in 47·2% and 40·6% of the 123 patients, respectively. Overall response rate to rhTPO treatment in patients without anti-GPIb/IX autoantibodies was significantly higher than patients with anti-GPIb/IX autoantibodies (82·2% vs. 60·0%, P = 0·006). By contrast, no statistical difference in response rate was observed between patients with or without anti-GPIIb/IIIa autoantibodies (74·1% vs. 72·3%, P = 0·819). Therefore, the presence of anti-GPIb/IX autoantibodies might serve as a predictive factor for poor response to rhTPO treatment in ITP.
本回顾性研究旨在评估一线治疗失败的成人 ITP 患者血浆自身抗体种类与 rhTPO 反应之间的关系。在 123 名患者中，分别检测到 47.2%和 40.6%的血浆抗糖蛋白（GP）IIb/IIIa 和抗 GPIb/IX 自身抗体。无抗 GPIb/IX 自身抗体的患者 rhTPO 治疗的总体反应率显著高于有抗 GPIb/IX 自身抗体的患者（82.2% vs. 60.0%，P=0.006）。相比之下，有或无抗 GPIIb/IIIa 自身抗体的患者之间的反应率无统计学差异（74.1% vs. 72.3%，P=0.819）。因此，抗 GPIb/IX 自身抗体的存在可能是 ITP 患者对 rhTPO 治疗反应不佳的预测因素。
Zotero 插件